<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250526065916N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-07-27</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of laser on tooth movement rate during orthodontic treatment</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of canine retraction using Er:Yag and Photobiomodulation in patients undergoing orthodontic treatment</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>24</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/83888</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The simple randomization method will be used with random blocks. Using Stata software, 8 blocks of 3 will be randomly generated. Then, a block will be randomly selected from the list and people will be assigned to groups based on the block, Blinding description: This study will be conducted in a double-blind manner. The patients and the person administering the interventions will be aware of the patient groups. However, the person who will follow up the patients and record the changes that occur, as well as the statistical consultant who will be responsible for comparing the results, will not be aware of the study groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>orthodontic issues.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Low-level laser therapy (LLLT). Low-level laser therapy (LLLT) will be performed twice a week for four weeks using a continuous-wave mode laser (EPIC X, Biolase, USA) with the following characteristics: 940 nm, power 200 mW, and tip cross-section area 4 cm2 with an energy density of 4 J/cm2. Intervention 2: Intervention group 2: Er:YAG. In this group, ER:YAG laser (WaterLase, Biolase, USA) with MT4 gold handpiece (diameter: 400 microns, length: 6 mm) will be applied twice a week for four weeks. Intervention 3: Intervention group 3: Low-level laser therapy (LLLT) + ER:YAG laser. In this group, both methods mentioned in the first and second intervention groups will be applied simultaneously according to the protocols mentioned in the first and second intervention groups. In this group, low-level laser therapy (LLLT) is performed via a continuous-wave mode laser (EPIC X, Biolase, USA) with the following characteristics: 940 nm, power 200 mW, and tip cross-section 4 cm2 with an energy density of 4 J/cm2. Then, ER:YAG (WaterLase, Biolase, USA) is applied with a gold handpiece MT4 (diameter: 400 microns, length: 6 mm). Both lasers will be applied twice a week for four weeks. Intervention 4: Control group: In all groups, the opposite quadrant will be considered as the control. In fact, out of 32 participants, one side of the patient's jaw will be considered as the intervention and the opposite side as the control. The choice of the control or model side will be determined by a coin toss. There will be no intervention on the control side.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information available.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Avideh Maboudi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Deputy for Research and Technology Building, Moalem Square, Sari, Mazandaran province</address>
        <city>sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۴۸۱۵۷۳۳۹۷۱</zip>
        <telephone>+98 11 3304 4030</telephone>
        <email>avideh.maboudi@gmail.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Melika Mollaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Deputy for Research and Technology Building, Moalem Square, Sari, Mazandaran province</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۴۸۱۵۷۳۳۹۷۱</zip>
        <telephone>+98 11 3324 4014</telephone>
        <email>Melika.mollaei.7@gmail.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>age of 14 to 27 years old
Healthy patients with appropriate oral hygiene and periodontal condition
Class II div I individuals who require bilateral maxillary first premolar extraction followed by canine retraction.
no history of orthodontic treatment</inclusion_criteria>
      <agemin>14 years</agemin>
      <agemax>27 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>presence of systemic diseases
Patients with dental phobia</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M26.212</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Malocclusion, Angle's class II</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Low-level laser therapy (LLLT). Low-level laser therapy (LLLT) will be performed twice a week for four weeks using a continuous-wave mode laser (EPIC X, Biolase, USA) with the following characteristics: 940 nm, power 200 mW, and tip cross-section area 4 cm2 with an energy density of 4 J/cm2</i_keyword>
      <i_keyword>Intervention group 2: Er:YAG. In this group, ER:YAG laser (WaterLase, Biolase, USA) with MT4 gold handpiece (diameter: 400 microns, length: 6 mm) will be applied twice a week for four weeks.</i_keyword>
      <i_keyword>Intervention group 3: Low-level laser therapy (LLLT) + ER:YAG laser. In this group, both methods mentioned in the first and second intervention groups will be applied simultaneously according to the protocols mentioned in the first and second intervention groups. In this group, low-level laser therapy (LLLT) is performed via a continuous-wave mode laser (EPIC X, Biolase, USA) with the following characteristics: 940 nm, power 200 mW, and tip cross-section 4 cm2 with an energy density of 4 J/cm2. Then, ER:YAG (WaterLase, Biolase, USA) is applied with a gold handpiece MT4 (diameter: 400 microns, length: 6 mm). Both lasers will be applied twice a week for four weeks.</i_keyword>
      <i_keyword>Control group: In all groups, the opposite quadrant will be considered as the control. In fact, out of 32 participants, one side of the patient's jaw will be considered as the intervention and the opposite side as the control. The choice of the control or model side will be determined by a coin toss. There will be no intervention on the control side.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Canine retraction rate. Timepoint: Before intervention, 1 month after intervention, 2 months after intervention. Method of measurement: Orthodontic software package.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-04-06</approval_date>
        <contact_name>Ethics committee of Mazandaran University of Medical Sciences</contact_name>
        <contact_address>Deputy for Research and Technology Building, Moalem Square, Sari, Mazandaran province Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
